E9-12671. Small Entity Compliance Guide: Bottled Water: Residual Disinfectants and Disinfection Byproducts; Availability  

  • Start Preamble

    AGENCY:

    Food and Drug Administration, HHS.

    ACTION:

    Notice.

    SUMMARY:

    The Food and Drug Administration (FDA) is announcing the availability of a guidance for industry entitled “Bottled Water: Residual Disinfectants and Disinfection Byproducts—Small Entity Compliance Guide” for a direct final rule published in the Federal Register of March 28, 2001. This small entity compliance guide (SECG) is intended to set forth in plain language the requirements of the regulation and to help small businesses understand the regulation.

    DATES:

    Submit written or electronic comments on the SECG at any time.

    ADDRESSES:

    Submit written comments on the SECG to the Division of Dockets Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852. Submit electronic comments on the SECG to http://www.regulations.gov. Submit written requests for single copies of the SECG to the Division of Plant and Dairy Food Safety (HFS-317), Office of Food Safety, Center for Food Safety and Applied Nutrition, Food and Drug Administration, 5100 Paint Branch Pkwy., College Park, MD 20740, or fax your request to 301-436-2651. Send one self-addressed adhesive label to assist that office in processing your request. See the SUPPLEMENTARY INFORMATION section for electronic access to the SECG.

    Start Further Info

    FOR FURTHER INFORMATION CONTACT:

    Lauren Posnick Robin, Center for Food Safety and Applied Nutrition (HFS-317), Food and Drug Administration, 5100 Paint Branch Pkwy., College Park, MD 20740, 301-436-1639.

    End Further Info End Preamble Start Supplemental Information

    SUPPLEMENTARY INFORMATION:

    I. Background

    In the Federal Register of March 28, 2001 (66 FR 16858), FDA issued a direct final rule amending its bottled water quality standard regulations by establishing allowable levels for three residual disinfectants (chloramine, chlorine, and chlorine dioxide) and three types of disinfection byproducts (DBPs) (bromate, chlorite, and haloacetic acids (HAA5)), and by revising the existing allowable level for the DBP total trihalomethanes (TTHM). FDA also revised, for the three residual disinfectants and four types of DBPs only, the monitoring requirement for source water found in the current good manufacturing practice (CGMP) regulations for bottled water. On July 5, 2001 (66 FR 35373), FDA issued a technical amendment to correct an editorial error and confirmed the effective date of January 1, 2002.

    FDA examined the economic implications of the direct final rule as required by the Regulatory Flexibility Act (5 U.S.C. 601-612) and determined that the rule would have a significant economic impact on a substantial number of small entities. In compliance with section 212 of the Small Business Regulatory Enforcement Fairness Act (Public Law 104-121), FDA is making available this SECG stating in plain language the legal requirements of the March 28, 2001, direct final rule set forth in 21 CFR parts 129 and 165 concerning the allowable levels and monitoring requirements for the three residual disinfectants (chloramine, chlorine, and chlorine dioxide) and four types of DBPs (bromate, chlorite, HAA5, and TTHM).

    FDA is issuing this SECG as level 2 guidance consistent with FDA's good guidance practices regulation (21 CFR 10.115(c)(2)). The SECG represents the agency's current thinking on this topic. It does not create or confer any rights for or on any person and does not operate to bind FDA or the public. An alternative approach may be used if such approach satisfies the requirements of the applicable statutes and regulations.

    II. Comments

    Interested persons may submit to the Division of Dockets Management (see ADDRESSES) written or electronic comments regarding this SECG. Submit a single copy of electronic comments or two paper copies of any mailed comments, except that individuals may submit one paper copy. Comments are to be identified with the docket number found in brackets in the heading of this document. The SECG and received comments may be seen in the Division of Dockets Management between 9 a.m. and 4 p.m., Monday through Friday.

    III. Electronic Access

    Persons with access to the Internet may obtain the document at http://www.cfsan.fda.gov/​guidance.html or http://www.regulations.gov.

    Start Signature

    Dated: May 22, 2009.

    Jeffrey Shuren,

    Associate Commissioner for Policy and Planning.

    End Signature End Supplemental Information

    [FR Doc. E9-12671 Filed 5-29-09; 8:45 am]

    BILLING CODE 4160-01-S

Document Information

Comments Received:
0 Comments
Published:
06/01/2009
Department:
Food and Drug Administration
Entry Type:
Notice
Action:
Notice.
Document Number:
E9-12671
Dates:
Submit written or electronic comments on the SECG at any time.
Pages:
26252-26252 (1 pages)
Docket Numbers:
Docket No. FDA-2009-D-0224
PDF File:
e9-12671.pdf